Global Development Lead (GDL), Clinical Development

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced oncology drug-development leader to serve as Global Development Lead (GDL) for one of Revolution Medicines’ most advanced clinical programs. This is a senior, program-accountable leadership role with end-to-end ownership of clinical development strategy and execution for a late-stage asset, including pivotal studies, regulatory engagement, and long-range planning. The GDL functions as the single point of clinical accountability for the assigned program, setting direction, driving alignment across functions, and representing the program at internal governance bodies and externally with investigators, key opinion leaders, and global health authorities. This position sits at the Executive Director level within Clinical Development and carries program-level accountability and authority typically associated with the most senior clinical leaders in the organization. In addition to program ownership, the GDL serves as a senior clinical advisor to development leadership, contributing perspective to cross-program and enterprise-level development discussions as appropriate. Responsibilities Program & Clinical Strategy Own and lead the global clinical development strategy for the assigned program, integrating scientific, clinical, regulatory, biomarker, and commercial considerations. Partner closely with the Project Team Leader (PTL) or Lifecycle Team Leader (LCL) to ensure that clinical development strategy, positions and decision-making are fully represented and integrated within lifecycle planning and decision-making for the molecule, with clear alignment on roles, decision rights and accountability. Develop and maintain the Target Product Profile (TPP), Clinical Development Plan (CDP), risk assessments, scenario analyses, and long-range program roadmap. Present strategic recommendations to internal governance bodies (e.g., DRG, SMT, PRG, ePRG) and drive high-quality, timely program decision-making. Ensure strategy reflects deep disease-area insight, emerging science, competitive intelligence, and evolving regulatory expectations. Execution & Oversight Accountable for the design, execution, and delivery of pivotal and registration-enabling studies (Phase 2/3), including protocol strategy, enrollment and geographic planning, patient safety oversight, and data interpretation. Ensure alignment and harmonization across related studies within the program and across regions to support coherent regulatory and lifecycle objectives. Provide senior clinical leadership across functions to anticipate risk, resolve complex issues, and ensure delivery of critical milestones, leveraging matrixed teams rather than direct operational control. Guide preparation of regulatory briefing materials and serve as the senior clinical representative in global health authority interactions. Scientific & Medical Leadership Serve as the program’s senior medical authority, providing deep expertise in pancreatic and colorectal cancers. Translate scientific, translational, and biomarker insights into actionable clinical strategy. Engage key opinion leaders, investigators, advisory boards, and external experts to refine development strategy and strengthen scientific and clinic